市場調查報告書

抗高血壓藥的全球市場:分析與預測

Global Antihypertensive Drugs Market Research Report Forecast to 2023

出版商 Market Research Future 商品編碼 824894
出版日期 內容資訊 英文 124 Pages
訂單完成後即時交付
價格
抗高血壓藥的全球市場:分析與預測 Global Antihypertensive Drugs Market Research Report Forecast to 2023
出版日期: 2019年03月31日內容資訊: 英文 124 Pages
簡介

本報告提供全球抗高血壓藥市場相關調查分析,提供市場動態,市場趨勢,各市場區隔的市場分析,競爭情形,主要企業等系統性資訊。

第1章 序文

第2章 摘要整理

第3章 簡介

第4章 調查手法

第5章 市場動態

  • 概要
  • 推動要素
  • 阻礙因素
  • 機會

第6章 市場影響要素分析

  • 價值鏈分析
  • 波特的五力分析
  • 投資機會
  • 價格分析

第7章 全球抗高血壓藥市場:各治療水準

  • 概要
  • 利尿劑
  • ACE抑制劑 (血管收縮素轉化酵素抑制劑)
  • ARB
  • 鈣拮抗劑 (CCB)
  • β腎上腺素阻斷劑
  • 腎素抑制劑
  • 血液擴張藥
  • 其他

第8章 全球抗高血壓藥市場:各類型

  • 概要
  • 原發性高血壓
  • 次發性高血壓

第9章 全球抗高血壓藥市場:各流通管道

  • 概要
  • 零售藥局
  • 醫院藥局
  • 電子商務網站 & 網路藥店
  • 其他

第10章 全球抗高血壓藥市場:各地區

  • 簡介
  • 南北美洲
  • 歐洲
  • 亞太地區
  • 中東·非洲

第11章 競爭情形

  • 概要
  • 企業佔有率分析

第12章 企業簡介

  • Sanofi S. A.
  • Novartis AG
  • AstraZeneca
  • 第一三共
  • Boehringer Ingelheim GmbH
  • 武田醫藥品工業
  • Merck KGaA
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Pfizer, Inc.
  • United Therapeutics Corporation

第13章 附錄

目錄

Antihypertensive Drugs Market Research Report: by Therapeutic Class (Calcium Channel Blockers, Beta-adrenergic Blockers, Renin Inhibitors, ACE Inhibitors, Vasodilators, Diuretics, ARBs, Others), by Type (Primary Hypertension, Secondary Hypertension), by Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites & Online Drug Stores, Others), and Region - Global Forecast till 2023

Market analysis

Antihypertensive medications are prescribed by reputed clinicians for the management of hypertension or high blood pressure. The high pervasiveness of hypertension is the essential driver of the global antihypertensive medications market. Several awareness campaigns by several government and non-profit associations are probably going to work for the market. For example, the Pulmonary Hypertension Association (PHA) offers training programs and has a solid encouraging group of people which offers patients the right information about the treatment. The rising predominance of incessant illnesses is powering the interest of antihypertensive drugs or medications. What's more, the section of generics which has cut down patient expenses is anticipated to look good for the market over the forecast period (2018- 2023). The market is expected to grow at 2.67% CAGR during the forecast period.

Market segmentation

Based on its therapeutic classes, the global antihypertensive drugs market is segmented into beta-adrenergic blockers, calcium channel blockers, renin inhibitors, vasodilators, angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, diuretics, and others. On the basis of its type, the market is bifurcated into secondary and primary hypertension. Lastly, on the basis of its distribution channels, the market is bifurcated into hospital pharmacy, e-commerce websites and online drug stores, retail pharmacy, and others.

Regional analysis

Geographically, the global antihypertensive drugs market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Merck KGaA (Germany), Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Pfizer, Inc. (U.S.), and United Therapeutics Corporation (U.S.), Sanofi S.A. (France), Novartis AG (Switzerland), AstraZeneca (U.K.), Daiichi Sankyo Company, Ltd. (Japan), Boehringer Engelheim GmbH (Germany), Takeda Pharmaceutical Company (Japan), among others are some of the major players in the global antihypertensive drugs market.

Table of Contents

1 Report Prologue

2 Executive Summary

3 Market Introduction

  • 3.1 Definition
  • 3.2 Scope of the Study
  • 3.3 List of Assumptions
  • 3.4 Market Structure

4 Research Methodology

  • 4.1 Research Process
  • 4.2 Primary Research
  • 4.3 Secondary Research
  • 4.4 Market Size Estimation
  • 4.5 Forecast Model

5 Market Dynamics

  • 5.1 Overview
  • 5.2 Drivers
    • 5.2.1 Rising prevalence of hypertension
    • 5.2.2 Growing initiatives by private and government organizations
    • 5.2.3 Rise in the prevalence rates of chronic diseases
    • 5.2.4 Increasing penetration of generic versions of drugs
  • 5.3 Restraints
    • 5.3.1 Side-effects of treatment options
    • 5.3.2 High cost of treatment
    • 5.3.3 Loss of patents
    • 5.3.4 Rise in non-pharmacological therapy
  • 5.4 Opportunity
    • 5.4.1 Emerging therapies in the treatment hypertension

6 Market Factor Analysis

  • 6.1 Value chain analysis
    • 6.1.1 R&D and Designing
    • 6.1.2 Manufacturing
    • 6.1.3 Distribution & Sales
    • 6.1.4 Post Sales Review
  • 6.2 Porter's Five Forces Model
    • 6.2.1 Bargaining Power of Suppliers
    • 6.2.1 Bargaining Power of Buyers
    • 6.2.2 Threat of New Entrants
    • 6.2.3 Threat of Substitutes
    • 6.2.4 Intense Rivalry
  • 6.3 Investment Opportunities
  • 6.4 Pricing Analysis

7 Global Antihypertensive Drugs Market, by Therapeutic Class

  • 7.1 Overview
  • 7.2 Diuretics
  • 7.3 ACE Inhibitors
  • 7.4 ARBs
  • 7.5 Calcium Channel Blockers
  • 7.6 Beta-Adrenergic Blockers
  • 7.7 Renin Inhibitors
  • 7.8 Vasodilators
  • 7.9 Others

8 Global Antihypertensive Drugs Market, by Type

  • 8.1 Overview
  • 8.2 Primary Hypertension
  • 8.3 Secondary Hypertension

9 Global Antihypertensive Drugs Market, by Distribution Channel

  • 9.1 Overview
  • 9.2 Retail Pharmacy
  • 9.3 Hospital Pharmacy
  • 9.4 E-commerce Websites & Online Drug Stores
  • 9.5 Others

10 Global Antihypertensive Drugs Market, by Region

  • 10.1 Overview
  • 10.2 Americas
    • 10.2.1 North America
      • 10.2.1.1 US
      • 10.2.1.2 Canada
    • 10.2.2 Latin America
  • 10.3 Europe
    • 10.3.1 Western Europe
      • 10.3.1.1 Germany
      • 10.3.1.2 France
      • 10.3.1.3 UK
      • 10.3.1.4 Italy
      • 10.3.1.5 Spain
      • 10.3.1.6 Rest of Western Europe
    • 10.3.2 Eastern Europe
  • 10.4 Asia-Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia-Pacific
  • 10.5 Middle East & Africa
    • 10.5.1 Middle East
    • 10.5.2 Africa

11 Competitive Landscape

  • 11.1 Overview
  • 11.2 Company Share Analysis

12 Company Profile

  • 12.1 Sanofi S. A.
    • 12.1.1 Company Overview
    • 12.1.2 Financial Overview
    • 12.1.3 Products Offered
    • 12.1.4 SWOT Analysis
    • 12.1.5 Key Developments
    • 12.1.6 Key strategy
  • 12.2 Novartis AG
    • 12.2.1 Company Overview
    • 12.2.2 Financial Overview
    • 12.2.3 Products Offered
    • 12.2.4 SWOT Analysis
    • 12.2.5 Key Developments
    • 12.2.6 Key strategy
  • 12.3 AstraZeneca
    • 12.3.1 Company Overview
    • 12.3.2 Financial Overview
    • 12.3.3 Products Offered
    • 12.3.4 SWOT Analysis
    • 12.3.5 Key Developments
    • 12.3.6 Key strategy
  • 12.4 Daiichi Sankyo Company, Ltd
    • 12.4.1 Company Overview
    • 12.4.2 Financial Overview
    • 12.4.3 Products Offered
    • 12.4.4 SWOT Analysis
    • 12.4.5 Key Developments
    • 12.4.6 Key Strategy
  • 12.5 Boehringer Ingelheim GmbH
    • 12.5.1 Company Overview
    • 12.5.2 Financial Overview
    • 12.5.3 Products Offered
    • 12.5.4 SWOT Analysis
    • 12.5.5 Key Developments
    • 12.5.6 Key Strategy
  • 12.6 Takeda Pharmaceutical Company Ltd
    • 12.6.1 Company Overview
    • 12.6.2 Financial Overview
    • 12.6.3 Products Offered
    • 12.6.4 SWOT Analysis
    • 12.6.5 Key Developments
    • 12.6.6 Key Strategy
  • 12.7 Merck KGaA
    • 12.7.1 Company Overview
    • 12.7.2 Financial Overview
    • 12.7.3 Products Offered
    • 12.7.4 SWOT Analysis
    • 12.7.5 Key Developments
    • 12.7.6 Key Strategy
  • 12.8 Johnson & Johnson Services, Inc.
    • 12.8.1 Company Overview
    • 12.8.2 Financial Overview
    • 12.8.3 Products Offered
    • 12.8.4 SWOT Analysis
    • 12.8.5 Key Developments
    • 12.8.6 Key Strategy
  • 12.9 Bayer AG
    • 12.9.1 Company Overview
    • 12.9.2 Financial Overview
    • 12.9.3 Products Offered
    • 12.9.4 SWOT Analysis
    • 12.9.5 Key Developments
    • 12.9.6 Key Strategy
  • 12.1 Pfizer, Inc.
    • 12.10.1 Company Overview
    • 12.10.2 Financial Overview
    • 12.10.3 Products Offered
    • 12.10.4 SWOT Analysis
    • 12.10.5 Key Developments
    • 12.10.6 Key Strategy
  • 12.11 United Therapeutics Corporation
    • 12.11.1 Company Overview
    • 12.11.2 Financial Overview
    • 12.11.3 Products Offered
    • 12.11.4 SWOT Analysis
    • 12.11.5 Key Developments
    • 12.11.6 Key Strategy

13 Appendix

  • 13.1 Discussion Blue Print